Immuron Ltd
ASX:IMC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Immuron Ltd
ASX:IMC
|
AU |
|
H
|
Hangzhou Lion Electronics Co Ltd
SSE:605358
|
CN |
|
P
|
Pico Thailand PCL
SET:PICO
|
TH |
|
R
|
Richter Gedeon Vegyeszeti Gyar Nyrt
BET:RICHTER
|
HU |
|
EFORT Intelligent Equipment Co Ltd
SSE:688165
|
CN |
|
Vakko Tekstil ve Hazir Giyim Sanayi Isletmeleri AS
IST:VAKKO.E
|
TR |
|
J
|
Jiangsu Favored Nanotechnology Co Ltd
SSE:688371
|
CN |
|
H
|
Humble Group AB
STO:HUMBLE
|
SE |
|
Bellway PLC
LSE:BWY
|
UK |
|
China Leadshine Technology Co Ltd
SZSE:002979
|
CN |
|
Indigo Paints Ltd
NSE:INDIGOPNTS
|
IN |
|
T
|
Torpol SA
WSE:TOR
|
PL |
|
R
|
Revolution Co Ltd
TSE:8894
|
JP |
|
MDJM Ltd
NASDAQ:UOKA
|
UK |
|
Regency Centers Corp
NASDAQ:REG
|
US |
|
Shanghai Xintonglian Packaging Co Ltd
SSE:603022
|
CN |
|
M
|
Military Metals Corp
CNSX:MILI
|
CA |
|
Galapagos NV
AEX:GLPG
|
BE |
|
First Service Holding Ltd
HKEX:2107
|
CN |
Immuron Ltd
Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in technology platform focused on the development and commercialization of a novel polyclonal antibodies to treat unmet medical needs. The firm operates through two segments: Research and development (R&D) and Hyperimmune product. R&D segment focuses on R&D projects performed in Australia, Israel, and United States. Hyperimmune product segment is engaged in Travelan and Protectyn activities, which occurs in Australia, the Unites States and Canada. The firm's flagship products include Travelan & Protectyn. Travelan is an over the counter immune supplement that can be taken to reduce the risk of diarrhea and reduce the symptoms of minor gastrointestinal disorders. Protectyn is an anti-LPS antibodies, which target and remove harmful bacteria and LPS toxins in the gut. The firm focused on clinical development of three drug candidates and several in early-stage preclinical development.
Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in technology platform focused on the development and commercialization of a novel polyclonal antibodies to treat unmet medical needs. The firm operates through two segments: Research and development (R&D) and Hyperimmune product. R&D segment focuses on R&D projects performed in Australia, Israel, and United States. Hyperimmune product segment is engaged in Travelan and Protectyn activities, which occurs in Australia, the Unites States and Canada. The firm's flagship products include Travelan & Protectyn. Travelan is an over the counter immune supplement that can be taken to reduce the risk of diarrhea and reduce the symptoms of minor gastrointestinal disorders. Protectyn is an anti-LPS antibodies, which target and remove harmful bacteria and LPS toxins in the gut. The firm focused on clinical development of three drug candidates and several in early-stage preclinical development.
